Professional Documents
Culture Documents
Dr Arun D Bhatt
MD (Med) FICP (Ind)
Member Faculty of Pharmaceutical
Medicine (Royal College UK)
President
ClinInvent Research India Pvt Ltd
1
Changes in Schedule Wh(Y)?
3
Significant Changes
4
Definition of Clinical Trial
5
Clinical Trials
§ Definition of Phases I – IV
§ Concurrent Phase II-III
§ Central lab and trial samples
§ Compliance to GCP / GLP
§ Flexibility in data requirements for
new drugs for life threatening /
serious conditions or disease of
relevance to India
6
Clinical Trials :
Special Studies
§ Clinical trials required if the indication is
relevant to special population e.g.
pediatrics, geriatrics, pregnancy
§ EC for paediatric trials to include
members knowledgeable about paediatric,
ethical, clinical and psychosocial issues
§ Mature minors and adolescents to sign an
assent form
§ Other – Post-marketing surveillance,
BA/BE
7
Responsibility of Sponsor
10
Ethics Committee
11
Appendices
12
Appendices
§ I Data for submission for application to conduct
clinical trials / import / manufacture of new drugs
for marketing in the country
§ I-a Data for submission for application for grant
of permission to import and / or manufacture a
new drug already approved in the country.
§ II Structure, Contents And Format For Clinical
Study Reports
§ III Animal Toxicology (Non-clinical Toxicity
Studies)
§ IV Animal Pharmacology
13
Appendices
§ V Informed Consent
§ VI Fixed Dose Combinations (FDCs)
§ VII Undertaking by Investigator
§ VIII Ethics Committee
§ IX Stability Testing Of New Drugs
§ X Contents Of The Proposed Protocol For
Clinical Trial
§ XI Data Elements For Reporting Serious Adverse
Events Occurring In A Clinical Trial
14
Appendix II
Format For Clinical Study Reports
1. Title page
2. Synopsis
3. Statement of Compliance to GCP
4. Abbreviations
5. Table of contents
6. Ethics committee
7. Study team
15
Appendix II
Format For Clinical Study Reports
8. Introduction
9. Objective
10. Plan
11. Subjects
12. Efficacy
13. Safety
14. Discussion
15. List of References
16
Appendices for Clinical Study Reports
17
Appendix V Essential
Elements of Informed Consent
§ Trial involves research
§ Purpose
§ Trial treatments and randomization
§ Trial procedures
§ Risk
§ Benefit
§ Alternative treatments
§ Compensation / treatment for injury
§ Subject’s responsibilities
§ Experimental aspects
§ Any payment
18
Appendix V Essential
Elements of Informed Consent
§Confidentiality
§New information
§Voluntary participation
§Person/s to contact
Ø for study information
Ø rights of subject
Ø if study related injury
§Reasons for termination
§Duration of study
§Number of subjects
§Any other pertinent information
19
Appendix V
Format Of Informed Consent Form
§Study Title: Study Number:
§Subject’s Initials: Subject’s Name: Date of Birth / Age:
§ Consent Statements with initials in [ ]
§Signature (or Thumb impression) of the Subject / Legally
Acceptable Representative: Date:
§ Signatory’s Name:
§Signature of the Investigator: Date:
§Study Investigator’s Name:
§ Signature of the Witness: Date:
§ Name of the Witness:
20
Appendix VII
Undertaking By The Investigator
1. Full name, address and title of the Principal Investigator (or
Investigator(s) when there is no Principal Investigator)
2. Name and address of the medical college, hospital or other facility
where the clinical trial will be conducted: Education, training &
experience that qualify the Investigator for the clinical trial (Attach
details including Medical Council registration number, and / or any
other statement(s) of qualification(s))
3. Name and address of all clinical laboratory facilities to be used in
the study.
4. Name and address of the Ethics Committee that is responsible for
approval and continuing review of the study.
5. Names of the other members of the research team (Co- or sub-
Investigators) who will be assisting the Investigator in the conduct
of the investigation (s).
6. Protocol Title and Study number (if any) of the clinical trial to be
conducted by the Investigator
8. Signature with Date
21
Appendix VII.7
Commitments by The Investigator
i. Study not to begin until EC / DCGI approval
ii. Adherence to protocol
iii. Personal supervision
iv. Ensure requirements of IC and EC review
v. Report of AE to sponsor
vi. Understanding of investigator’s brochure
vii. Ensure that all associates, colleagues and
employees suitably qualified and experienced
and aware of their obligations
22
Commitments by Investigator
23
Appendix VIII
Ethics Committee
24
Quorum for EC
25
Documents for Review by Ethics
Committee
26
GCP - A Shared Responsibility
Sponsor
Investigator
Regulatory
Authority
Ethics
Committee
27